Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
Researchers want to find the best doses of different drugs to use together in people with advanced urothelial cancer. The people in this study have urothelial cancer that metastasized (spread) and has not yet been treated.
Researchers are assessing treatment with BGB-16673 in combination with other anti-cancer medications in people with B-cell cancers. These cancers include:
The purpose of this study is to assess the safety and effectiveness of the drug trastuzumab deruxtecan (also known as DS-8201A) in patients with inoperable or metastatic solid tumors that produce too much of a protein called HER2, including biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers.
Researchers are doing this study to see if the combination of epcoritamab, zanubrutinib, and rituximab works well against lymphoma. The people in this study have follicular lymphoma that has come back or keeps growing after treatment.
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.
Doctors want to know if giving emapalumab as upfront pre-treatment works well for people with severe acquired aplastic anemia (sAA). This medication is given after diagnosis, but before standard sAA treatment. In people with sAA, stem cells are destroyed and the body cannot make new blood cells.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Primary immune regulatory disorder (PIRD) and autoinflammatory conditions are conditions of the immune system that can cause an unusual amount of inflammation. While a stem cell transplant is a standard treatment for people with a PIRD or autoinflammatory condition, the inflammation caused by these conditions can reduce the effectiveness of this treatment.
Chronic graft-versus-host disease (cGVHD) is a condition in which healthy transplanted stem cells attack the recipient's healthy cells. cGVHD most often happens more than 100 days after a stem cell transplant, but it can happen at any time.
